
Provider Services: 1-800-454-3730 https://provider.amerigroup.com/GA



# **Provider Newsletter**



### **Table of Contents COVID-19 information from** Page 2 **Amerigroup Community Care** Prior authorization updates for Page 2 specialty pharmacy Medical drug benefit Clinical Criteria Page 2 updates Access to more claim denial Page 3 information is now self-service **Medical Policies and Clinical Utilization Management Guidelines** Page 4 update





## **COVID-19 information from Amerigroup Community Care**

Amerigroup is closely monitoring COVID-19 developments and how the novel coronavirus will impact our customers and provider partners. Our clinical team is actively monitoring external queries and reports from the Centers for Disease Control and Prevention (CDC) and the Georgia Department of Public Health to help us determine what action is necessary on our part. Amerigroup will continue to follow Georgia Department of Public Health guidance policies.

For additional information, reference the COVID-19 News and Resources section on the homepage of our website.

GAPEC-3065-20

## Prior authorization updates for specialty pharmacy

Effective for dates of service on and after April 1, 2021, the following medical injectable codes from current or new *Clinical Criteria* documents will be included in our prior authorization review process.

Please note, inclusion of the National Drug Code (NDC) on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

Visit the *Clinical Criteria* website to search for specific *Clinical Criteria*.

Clinical Criteria	HCPCS or CPT® code(s)	Drug
ING-CC-0164	J9281	Jelmyto (mitomycin)
ING-CC-0165	J9317	<b>Trodelvy</b> (sacituzumab Govitecan-hziy)
ING-CC-0061	J1950	Fensolvi (leuprolide acetate)

GA-NL-0335-20

## Medical drug benefit *Clinical Criteria* updates

### November 2020 update

On June 18, 2020, August 21, 2020, and November 20, 2020, the Pharmacy and Therapeutics (P&T) Committee approved several *Clinical Criteria* applicable to the medical drug benefit for Amerigroup Community Care. These policies were developed, revised or reviewed to support clinical coding edits.



GA-NL-0431-21

Visit the *Clinical Criteria* website to search for specific policies. If you have questions or would like additional information, reach out via email.



### Access to more claim denial information is now self-service


### Through predictive analytics, healthcare teams can now receive real-time solutions to claim denials.

Amerigroup Community Care is committed to providing digital first solutions. Healthcare teams can now use self-service tools to reduce the amount of time spent following up on claim denials. Through the application of predictive analytics, Amerigroup has the answers before you ask the questions. With an initial focus on claim-level insights, Amerigroup has streamlined claim denial inquiries by making the reasons for the claim denial digitally available. In addition

Through the application of predictive analytics,
Amerigroup has the answers before you ask the questions.

to the reason for the denial, we supply you with the next steps needed to move the claim to payment. This eliminates the need to call for updates and experience any unnecessary delays waiting for the *EOP*.

Access the *Claims Status Listing* on Payer Spaces from https://providers.amerigroup.com/ga by using the Log In button or through the secure provider portal via Availity.\* We provide a complete list of claims, highlight those claims that have proactive insights, provide a reason for the denial, and the information needed to move the claim forward.



### **Claim resolution daily**

Automated updates make it possible to refresh claims history daily. As you resolve claim denials, the claim status changes, other claims needing resolution are added, and claims are resolved faster.

Amerigroup made it easier to update and supply additional information, too. While logged into the secure provider portal, you have the ability to revise your claim, add attachments, or eliminate it if filed in error. Even if you did not file the claim digitally, you can access the proactive insights. Predictive analytics supplies the needed claim denial information online — all in one place.

Predictive proactive issue resolution and near real-time digital claim denial information is another example of how Amerigroup is using digital technology to improve the healthcare experience. If you have questions, please reach out to your Provider Relations representative.

\* Availity, LLC is an independent company providing administrative support services on behalf of Amerigroup Community Care.

GA-NL-0319-20



### Medical Policies and Clinical Utilization Management Guidelines update

The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.

To view a guideline, visit <a href="https://medicalpolicies.amerigroup.com/am\_search.html">https://medicalpolicies.amerigroup.com/am\_search.html</a>.

### **Notes/updates:**

Updates marked with an asterisk (\*) notate that the criteria may be perceived as more restrictive.

- \*GENE.00055 Gene Expression Profiling for Risk Stratification of Inflammatory Bowel Disease (IBD) Severity
  - Gene expression profiling for risk stratification of inflammatory bowel disease (IBD) severity, including use of PredictSURE IBD, is considered investigational and not medically necessary for all indications
- \*LAB.00037 Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS)
  - Serological testing for biomarkers of irritable bowel syndrome (for example, CdtB and anti-vinculin), using tests such as, IBSDetex, ibs-smart or IBSchek, is considered investigational and not medically necessary for screening, diagnosis or management of irritable bowel syndrome, and for all other indications
- \*DME.00011 Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices
  - Revised scope to only include nonimplantable devices and moved content addressing implantable devices to SURG.00158
  - Added "non-implantable" to bullet point on percutaneous neuromodulation therapy
  - Added percutaneous electrical nerve field stimulation (PENFS) as investigational and not medically necessary for all indications
- \*SURG.00062 Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

- Expanded scope to include percutaneous testicular vein embolization for varicocele and added embolization of the testicular (spermatic) veins as investigational and not medically necessary as a treatment of testicular varicocele
- \*CG-LAB-15 Red Blood Cell Folic Acid Testing
  - RBC folic acid testing is considered not medically necessary in all cases
- \*CG-LAB-16 Serum Amylase Testing
  - Serum amylase testing is considered not medically necessary for acute and chronic pancreatitis and all other conditions
- \*CG-GENE-04 Molecular Marker Evaluation of Thyroid Nodules
  - Added the Afirma Xpression Atlas as not medically necessary
- SURG.00158 Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain
  - A new Medical Policy was created from content contained in DME.00011.
  - There are no changes to the policy content.
  - Publish date is December 16, 2020.
- CG-GENE-21 Cell-Free Fetal DNA-Based Prenatal Testing
  - A new Clinical Guideline was created from content contained in GENE.00026.
  - There are no changes to the guideline content.
  - Publish date is December 16, 2020.
- The following AIM Specialty Health<sub>®</sub> (AIM)\* Clinical Appropriateness Guidelines have been revised and will be effective on April 7, 2021. To view AIM guidelines, visit the AIM page:
  - \*Advanced Imaging of the Heart
  - \*Diagnostic Coronary Angiography



### Medical Policies and Clinical Utilization Management Guidelines update (cont.)



#### **Medical Policies**

On November 5, 2020, the Medical Policy and Technology Assessment Committee (MPTAC) approved several *Medical Policies* applicable to Amerigroup Community Care. These guidelines take effect April 7, 2021.

### Clinical UM Guidelines

On November 5, 2020, the MPTAC approved several *Clinical UM Guidelines* applicable to Amerigroup. These guidelines were adopted by the Medical Operations Committee for Amerigroup members on November 19, 2020. These guidelines take effect April 7, 2021.

\* AIM Specialty Health is an independent company providing some utilization review services on behalf of Amerigroup Community Care.

GA-NL-0340-21

